Takeaways from HLTH 2021

John Elliott, VP of Sales at Carevive, attended the HLTH conference and shared his perspective on the event. The conference featured a unique blend of in-person and virtual components, providing a comprehensive business audience with diverse interests and expertise in the healthcare ecosystem. John highlighted the enthusiasm, problem-solving mindset, and investment opportunities that made the conference an exciting and valuable experience.

Key Takeaways:
The attendees at HLTH exhibited great enthusiasm and excitement, showcasing a mix of in-person and virtual engagement. John emphasized the importance of capturing insights from the sessions, which will be available for two months following the event. He expressed curiosity about the experience of those attending the conference solely virtually.

Comprehensive Business Audience:
John appreciated the comprehensive business audience at HLTH, which extended beyond traditional healthcare IT vendors and leaders. The conference attracted investors, health system innovators, and internal teams focused on optimizing processes and implementing technology solutions. The presence of investment professionals from outside the healthcare industry highlighted the potential and need for problem-solving within the healthcare landscape.

The Excitement of Problem-Solving:
John found the problem-solving mindset prevalent at HLTH to be particularly exciting. Attendees were eager to explore investment opportunities, mix and match various vendors, and drive innovation within their organizations. The expanding role of innovation teams, in addition to traditional health system leadership, demonstrated a growing focus on optimizing healthcare delivery.

Recent Episodes

In this impactful episode of the ConCensis podcast, host Yasmeen Hassan sits down with Robby Miller, Sterile Processing Manager at St. Joseph’s Hospital Medical Center, to explore how artificial intelligence is revolutionizing the field of sterile processing. With nearly 30 years of experience in healthcare, Miller shares his journey from EMT to SPD leader, offering…

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

In an era where precision and predictability define the future of oncology, organoid technology is emerging as a transformative tool in drug discovery. These miniature, lab-grown 3D tissues mirror real human biology more closely than traditional 2D models or even animal systems, offering researchers the potential to predict patient-specific drug responses. As organoids become more…